Signs, symptoms, and treatment patterns across serial ambulatory cardiology visits in patients with heart failure: insights from the NCDR PINNACLE® registry

Larry A. Allen 1*, Fengming Tang 2, Philip Jones 2, Tracie Breeding 2, Angelo Ponirakis 3 and Stuart J. Turner 4

Abstract

Background: Due to a relative lack of outpatient heart failure (HF) clinical registries, we aimed to describe symptoms, signs, and medication treatment among ambulatory patients with heart failure (HF) over time.

Methods: Using health records from 234 PINNACLE (Practice Innovation and Clinical Excellence) U.S. cardiology practices (2008–2014), serial visits for patients with HF were characterized. Symptoms, signs, and HF medications (angiotensin-converting enzyme inhibitors [ACEI], angiotensin receptor blockers [ARB], beta blockers [BB], and diuretics) were compared between visits.

Results: Among 763,331 patients with HF, 550,581 had ≥2 clinic visits <1 year apart, with 2,998,444 visit pairs. In the 12 months following an index visit, patients had a mean of 2.5 ± 2.3 additional visits. Recorded index visit symptoms ranged from dyspnea (53.6%) to orthopnea (23.1%); signs ranged from peripheral edema (52.2%) to hepatomegaly (0.6%). Of those with ejection fraction <40%, ACEI was prescribed in 58.6%, ARB in 18.5%, BB in 85.2%, and diuretics in 70.0%. Between-visit recorded changes were infrequent: dyspnea appeared in 3.8%, resolved in 2.7%; NYHA class increased in 2.9%, decreased in 2.9%; number of signs increased in 6.0%, decreased in 5.1%; ACEI/ARB or BB added in 6.4%, removed in 6.2%; diuretic added in 3.7%, removed in 3.8%. Changes in recorded symptoms were rarely associated with initiation or discontinuation in HF medication classes.

Conclusions: Ambulatory HF care in U.S. cardiology practices seldom recorded changes in symptoms, signs, and medication class. Although templated medical records and absence of medication dosing likely underestimated the degree to which clinical changes occur over serial visits for HF, these PINNACLE data suggest opportunities for greater symptom-based and therapy-focused visits.

Keywords: Ambulatory care, Drug therapy, Heart failure, Registries, Dyspnea

Background

The nearly 6 million Americans with heart failure (HF) account for more than 12 million physician office visits each year [1–4]. From patient and clinician perspectives, these medical encounters provide an opportunity to improve the medical management of HF, which in turn has the potential to relieve the symptoms of HF, improve health-related quality of life, reduce hospitalizations, and prolong survival [5–9]. Current clinical practice guidelines recommend the serial optimization of HF medication therapies, involving dose titration and monitoring to achieve maximum symptom relief and medication tolerability [5, 7, 8, 10].

A number of patient registries have been established to characterize patients with HF and the care received in routine clinical practice. However, due to a variety of logistical issues, they have been primarily limited to in-hospital care, administrative billing data, or a small number of sites, and thus have been unable to provide a comprehensive look at ambulatory HF care across the
U.S. [11–14]. The American College of Cardiology’s National Cardiovascular Data Registry’s (NCDR®) PINNACLE Registry (Practice Innovation and Clinical Excellence) Registry is now the largest contemporary clinical database of ambulatory cardiology care, which includes detailed information on symptoms, signs, medication prescribing, procedures, and outcomes from patients diagnosed with a variety of cardiovascular (CV) conditions [15–19]. Using this emerging real-world ambulatory view provided by the PINNACLE Registry, we sought to characterize changes in recorded symptoms, physical signs, and prescribing of medication classes across serial ambulatory cardiology visits for patients with HF.

Methods

Study design

PINNACLE is the first U.S. national, prospective, office-based, quality improvement registry for CV ambulatory care in the U.S. Participation is voluntary, and data are routinely collected and submitted to the American College of Cardiology’s NCDR from participating practices using paper-based chart abstraction or a mapping algorithm from electronic health records [18]. The current study was a cross-sectional analysis of patients ≥18 years of age enrolled in the PINNACLE Registry with a diagnosis code for HF between May 1, 2008, and December 30, 2014. Included patients had at least 1 pair of ambulatory visits less than 1 year apart. Diagnosis of HF was defined using PINNACLE Registry criteria of unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention, and low cardiac output secondary to cardiac dysfunction; via the description of rales, jugular venous distension, or pulmonary edema constituted HF; or as a previous hospital admission with primary diagnosis of HF [20, 21]. The first visit in the first pair of ambulatory visits was defined as the index visit. Baseline characteristics were assessed at the time of the first visit (index visit). To assess changes in symptoms, signs, and treatment, all subsequent visits following the index visit were compared against the visit immediately prior if the 2 visits were less than 1 year apart. Data were extracted directly from the practices’ electronic health record or via a paper-based reporting form. Data collection was standardized using established definitions, uniform data entry and transmission, and quality checks. In addition, rigorous back-end data quality checks were performed on the extracted data. Any data not meeting predefined quality thresholds were quarantined from analyses and flagged for manual review and follow-up with individual practices [18]. Missing data for any visit were handled using a last observation carried forward approach, where available.

Study outcomes

The primary outcomes of interest were the associations between changes in the incidence of the signs and symptoms of HF and changes in medications at a class level. The signs and symptoms of HF assessed included changes in New York Heart Association (NYHA) functional class, the presence of dyspnea and orthopnea, as well as changes in the number of physical signs of HF present, including rales, ascites, peripheral edema, hepatomegaly, third heart sound (S₃ gallop), fourth heart sound (S₄ gallop), and jugular vein distention. Medications were classified as angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), beta blockers (BB), and diuretics.

Due to limitations in the granularity of medication capture, loop diuretics, thiazides, diuretics, and mineralocorticoid receptor antagonists were grouped as a single diuretics category during PINNACLE data collection. Therefore, MRA (spironolactone and eplerenone) cannot be distinguished from other diuretics, including commonly used loop diuretics (e.g., furosemide). Thus, “diuretics” represents a heterogeneous class in this analysis. At each visit, patients were assessed for presence or absence of a prescription for each of the 3 classes: 1) ACEI/ARB, 2) BB, and 3) diuretics. Medication treatment change between visits was classified into 1 of 3 groups: ‘increase’ (no to yes), ‘decrease’ (yes to no), or ‘no change’ in the number of HF medication classes prescribed. Currently, PINNACLE data capture does not allow for an analysis of HF medication dosing.

Data analyses

Demographics and clinical characteristics were represented as means and standard deviations (SD) for continuous variables and frequencies and percentages for categorical variables. The association between treatment patterns and change in HF symptoms and physical assessments was described using percentages of treatment ‘increase’, ‘decrease’, and ‘no change’ in HF symptoms and physical assessment categories. Rate ratios for treatment increase and treatment decrease were also calculated for patients with HF symptoms and physical assessment increase and decrease relative to those with no change. The frequency of HF treatment modifications in 1 year of follow-up after index, number of subsequent visits after index per patient, and time between 2 consecutive eligible visits using mean, interquartile range, and SD were also described. All analyses were then repeated and stratified by age group (≤65 and ≥65 years), and within the subset with reduced left-ventricular ejection fraction (LVEF < 40%).

A number of key variables in PINNACLE had non-trivial missing rates. To assess for potential bias, the demographics and clinical characteristics of the visits
included versus those of the visits excluded due to missing data were described using means (SD) for continuous variables and frequencies (percentages) for categorical variables. In the sensitivity analysis to evaluate the impact of potential bias due to missing values, we repeated the primary analysis using inverse probability weighting, which assigned higher weights to visits that were similar to those with missing values. The probability weights were calculated from a logistic regression model on the basis of patient demographics and clinical characteristics. Data collection was standardized through the use of standard definitions, uniform data entry and transmission requirements, and data quality checks.

Results

Frequency of cardiology visits among patients with HF
A total of 4,713,004 patients were identified in the PINNACLE Registry from 234 practices from May 1, 2008 to December 30, 2014. From 763,331 patients who had a documented diagnosis of HF, 550,581 patients (72.1%) from 224 practices had at least 2 ambulatory visits less than 1 year apart. The total number of qualified visit pairs was 2,998,444. The mean length of follow-up per patient was 1.9 ± 1.6 years. In the 12 months following an index visit, patients had a mean of 2.5 ± 2.3 additional visits.

Findings at index visit
The baseline demographics and clinical characteristics of the study population are presented in Table 1. The mean (SD) age of the population was 69.7 (13.4) years, 45.1% were women, and 87.4% were white. LVEF was available in 52.2% of the patients; 26.1% of patients with an LVEF measure had a LVEF < 40% at the index visit. The most common comorbidities were hypertension (82.2%) followed by dyslipidemia (65.0%) and coronary artery disease (60.9%).

Symptoms of dyspnea and orthopnea were reported in 53.6% and 23.1% of patients at the index visit, respectively. Patients were predominantly in NYHA functional class 1 (59.7%) at the index visit, with an additional 29.3% of patients in class 2. The most frequently reported physical sign of HF was peripheral edema (52.2%), followed by S₃ gallop (12.3%). At the index visit, an ACEI/ARB or BB were not prescribed for 17.5% of patients; 68.8% were prescribed BB, 43.6% were prescribed ACEI, and 20.7% were prescribed ARB; 47.3% of patients were on a combination of an ACEI/ARB plus a BB and 35.1% were on either an ACEI/ARB or a BB. Diuretics were prescribed for 56.4% of patients.

A number of variables in PINNACLE had a significant pattern as that observed for the overall population included versus those of the visits excluded due to missing data. Changes in symptoms and signs followed a similar pattern (Table 2). Rate ratios tended to follow a pattern that indicated an increased frequency of the addition of a medication class associated with symptom or sign worsening and a decreased frequency of the addition of a medication class associated with symptom or sign improvement, compared with no change in symptoms or signs (Table 2).

Patients with LVEF < 40%
For the 75,107 patients with an LVEF < 40%, baseline demographic and clinical characteristics were similar to the overall study population; however, there was a greater percentage of men in the LVEF < 40% subgroup (69.1% vs 54.9%). Patients with LVEF < 40% and available data were mainly NYHA functional class 2 (46.5%) or 1 (29.0%) and more likely to be prescribed HF medications: BB (85.2%), a diuretic (70.0%), an ACEI (58.6%), or an ARB (18.5%) (Table 1).

Consistent with the results of the overall study population, patients with LVEF < 40% also rarely reported changes in symptoms and signs of HF or in HF medication class, with the majority of patients reporting no changes after the index date (Table 3). The rate ratios for treatment increase or decrease associated with changes in HF symptoms and signs followed a similar pattern as that observed for the overall population (Table 3).
|                             | OVERALL STUDY POPULATION (n = 550,581) | Patients with Data Available (n = 75,107) | Patients with LVEF < 40% (n = 75,107) | Patients > 65 Years of Age (n = 374,580) |
|-----------------------------|---------------------------------------|-------------------------------------------|---------------------------------------|------------------------------------------|
| **Age, yrs**                | 69.7 ± 13.4                           | 100%                                      | 68.6 ± 13.1                           | 77.0 ± 7.6                               |
| **Sex**                     |                                       |                                            |                                       |                                          |
| Men                         | 54.9%                                 |                                            | 69.1%                                 | 53.2%                                    |
| **Race**                    |                                       |                                            |                                       |                                          |
| White                       | 87.4%                                 |                                            | 86.3%                                 | 91.1%                                    |
| Black                       | 10.1%                                 |                                            | 12.0%                                 | 6.7%                                     |
| Other                       | 2.5%                                  |                                            | 1.7%                                  | 2.2%                                     |
| **Ethnicity**               |                                       |                                            |                                       |                                          |
| Hispanic                    | 1.9%                                  |                                            | 2.2%                                  | 1.8%                                     |
| **Comorbidities**           |                                       |                                            |                                       |                                          |
| Hypertension                | 82.2%                                 |                                            | 77.1%                                 | 84.7%                                    |
| Dyslipidemia                | 65.0%                                 |                                            | 68.6%                                 | 68.4%                                    |
| Coronary artery disease     | 60.9%                                 |                                            | 70.7%                                 | 65.3%                                    |
| Atrial fibrillation/flutter | 34.2%                                 |                                            | 35.8%                                 | 41.2%                                    |
| Type 2 diabetes             | 28.1%                                 |                                            | 30.7%                                 | 28.2%                                    |
| Previous myocardial infarction | 21.7%                               |                                            | 31.4%                                 | 22.4%                                    |
| Stable angina               | 11.5%                                 |                                            | 11.2%                                 | 12.5%                                    |
| Peripheral arterial disease | 10.8%                                 |                                            | 11.4%                                 | 12.4%                                    |
| Stroke/transient ischemic attack | 6.1%                               |                                            | 5.8%                                  | 7.1%                                     |
| Ischemic stroke             | 2.5%                                  |                                            | 2.5%                                  | 2.9%                                     |
| Unstable angina             | 2.4%                                  |                                            | 2.4%                                  | 2.5%                                     |
| **NYHA functional class**   |                                       |                                            |                                       |                                          |
| 1                           | 59.7%                                 | 29.0%                                     | 54.0%                                 |                                          |
| 2                           | 29.3%                                 | 46.5%                                     | 33.1%                                 |                                          |
| 3                           | 10.0%                                 | 22.3%                                     | 11.8%                                 |                                          |
| 4                           | 1.0%                                  | 2.3%                                      | 1.1%                                  |                                          |
| **Symptoms**                |                                       |                                            |                                       |                                          |
| Dyspnea                     | 53.6%                                 | 85.7%                                     | 57.4%                                 | 55.2%                                    |
| Orthopnea                   | 23.1%                                 | 88.7%                                     | 24.5%                                 | 23.3%                                    |
| Systolic BP, mm Hg          | 127.7 ± 19.5                          | 93.0%                                     | 121.8 ± 19.0                          | 128.1 ± 19.4                             |
| Diastolic BP, mm Hg         | 73.2 ± 11.6                           | 93.0%                                     | 71.7 ± 11.8                           | 71.3 ± 10.9                              |
| Heart rate, bpm             | 72.9 ± 13.6                           | 86.6%                                     | 74.1 ± 13.6                           | 72.0 ± 13.2                              |
| **Physical signs**          |                                       |                                            |                                       |                                          |
| Rales                       | 4.9%                                  | 86.2%                                     | 6.2%                                  | 5.7%                                     |
| Ascites                     | 0.8%                                  | 92.9%                                     | 1.1%                                  | 0.8%                                     |
| Peripheral edema            | 52.2%                                 | 77.2%                                     | 54.2%                                 | 53.4%                                    |
| Hepatomegaly                | 0.6%                                  | 96.1%                                     | 1.0%                                  | 0.6%                                     |
| S1 gallop                   | 6.9%                                  | 91.8%                                     | 8.6%                                  | 7.3%                                     |
| S2 gallop                   | 12.3%                                 | 89.1%                                     | 11.6%                                 | 12.8%                                    |
| JVD                         | 6.8%                                  | 91.8%                                     | 8.4%                                  | 7.2%                                     |
| BMI, kg/m²                  | 30.8 ± 9.6                            | 74.3%                                     | 29.9 ± 9.0                            | 29.6 ± 9.0                               |
| Tobacco use                 | 52.1%                                 | 34.3%                                     |                                       | 40.0%                                    |

*Allen et al. BMC Cardiovascular Disorders (2018) 18:80*
Patients ≤65 and > 65 years of age

For the 374,580 patients > 65 years of age, with the exception of age (mean [SD]: 77.0 ± 7.6 years), baseline demographic and clinical characteristics were analogous to the overall study population. Changes in the prescribing of HF medication were similarly rarely observed irrespective of age. For patients ≤65 and > 65 years of age at index, the rate ratios for treatment increase or decrease associated with changes in HF symptoms and signs followed a similar pattern as that observed for the overall population (Tables 4 and 5).

Discussion

For patients with HF, the frequency of cardiology clinic visits, changes in symptoms and signs between visits, changes in HF medication class prescribing patterns at visits, and the relationship between them has not been previously described across the U.S. ambulatory cardiology setting. The current study found that the majority of patients with HF had 2 or more cardiology clinic visits in a year. Health records from these visits rarely recorded changes in dyspnea, orthopnea, NYHA functional class, or physical signs between visits. Further, HF medication class modifications were infrequent. Although predictable associations between changes in symptoms/signs and drug therapy were observed, particularly the addition of medication with increases in dyspnea and vice versa, the absolute rate of initiation and discontinuation of drug classes was small. This apparent lack of major HF treatment modification during ambulatory visits (recognizing the limitations of health record data generally and the absence of medication dosing here specifically) is a finding that warrants further investigation, either as a potential opportunity to more proactively optimize HF medication prescribing at cardiology visits (particularly in the HF population with reduced LVEF) or as an opportunity to reduce some routine follow-up visits in the absence of clinical change.

The vast majority of real-world HF data have been collected from inpatient settings, including the hospital-based registries such as the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) [11] and Get With The Guidelines®-Heart Failure (GWTG-HF) [14]. Ambulatory data have primarily been collected from randomized controlled trials, with limitations in external validity due to narrow inclusion criteria and algorithms for medication management [18, 22, 23]. A real-world ambulatory evaluation of care for patients with HF was provided through Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE-HF) [12, 19, 24], but those data represented a narrow cohort of participating centers and are becoming increasingly dated. PINNACLE represents the largest ambulatory data available for Americans diagnosed with a variety of CV conditions (coronary artery disease, hypertension, 

| Table 1 Baseline patient demographics and clinical characteristics (Continued) |
|---------------------------------|----------------|-----------------|----------------|
| Current                         | 14.4%          | 17.0%           | 11.2%          |
| Quit within 12 months           | 3.3%           | 4.0%            | 3.2%           |
| Quit more than 12 months ago    | 42.1%          | 44.7%           | 45.7%          |
| LVEF > 50%                      | 58.3%          | 60.5%           | 52.2%          |
| 40–49%                         | 15.6%          | 15.5%           | 15.5%          |
| < 40%                           | 26.1%          | 24.0%           | 24.0%          |
| Treatment                       | 100%           | 100%            | 100%           |
| ACEI                            | 43.6%          | 58.6%           | 42.3%          |
| ARB                             | 20.7%          | 18.5%           | 22.1%          |
| BB                              | 68.8%          | 85.2%           | 70.0%          |
| Diuretic                        | 56.4%          | 70.0%           | 60.0%          |
| PCI                             | 1.0%           | 1.3%            | 1.0%           |
| Pacemaker                       | 9.2%           | 24.1%           | 10.1%          |
| CRT-D                           | 9.5%           | 24.4%           | 10.4%          |
| ICD                             | 11.1%          | 29.7%           | 11.5%          |

ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta blocker, BMI body mass index, BP blood pressure, bpm beats per minute, CRT-D cardiac resynchronization therapy plus defibrillator, ICD implantable cardioverter defibrillators, JVD jugular vein distention, LVEF left ventricular ejection fraction, mm Hg millimeters of mercury, NYHA New York Heart Association, PCI percutaneous coronary intervention, S3 third heart sound, S4 fourth heart sound, yrs years
Table 2: Relationship of HF symptoms and signs and treatment patterns by visit pairings

| Treatment Patterns (ACEI, ARB, or BB) | Treatment Patterns (Diuretic) |
|--------------------------------------|-------------------------------|
| Increase (n = 193,516) b              | No Changes (n = 2,611,047)    |
| Increase (n = 24,422)                 | No Changes (n = 2,771,748)    |
| No changes (n = 789,561)              | Yes to No (n = 115,103)       |
| Decrease (n = 24,242)                 | Rate Ratio for Treatment      |
|                                      | Increase                     |
|                                      | Decrease                     |
| NYHA class change, % c               | No to Yes (n = 111,593)       |
| Increase (n = 24,422)                | No Changes (n = 2,771,748)    |
| No changes (n = 789,561)             | Yes to No (n = 115,103)       |
| Decrease (n = 24,242)                | Rate Ratio for Treatment      |
|                                      | Increase                     |
|                                      | Decrease                     |
| Dyspnea change, % c                  | No to yes (n = 90,972)        |
| No to yes (n = 90,972)               | No Changes (n = 2,244,909)    |
| No change (n = 2,244,909)            | Yes to no (n = 63,836)        |
| Yes to no (n = 63,836)               | Rate Ratio for Treatment      |
|                                      | Increase                     |
|                                      | Decrease                     |
| Orthopnea change, % c                | No to yes (n = 46,531)        |
| No to yes (n = 46,531)               | No Changes (n = 46,531)       |
| No change (n = 46,531)               | Yes to no (n = 39,180)        |
| Yes to no (n = 39,180)               | Rate Ratio for Treatment      |
|                                      | Increase                     |
|                                      | Decrease                     |
| Changes in signs, % c d              | Increase (n = 99405)          |
| Increase (n = 99405)                 | No Changes (n = 1,466,063)    |
| No changes (n = 1,466,063)           | Decrease (n = 84,426)         |
| Decrease (n = 84,426)                | Rate Ratio for Treatment      |
|                                      | Increase                     |
|                                      | Decrease                     |

N = visit pairings; individual patients often represented more than once

ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta blocker, NYHA New York Heart Association

bTreatment patterns were grouped into 1 of 3 categories: 'increase' (no to yes), 'decrease' (yes to no), or 'no change' in number of HF medication classes (ACEI, ARB, BB, and diuretic therapies)

bUnit of analysis throughout the table is cardiology outpatient visits

cChanges in number of physical signs of HF present out of 7 possible (rales, ascites, peripheral edema, hepatomegaly, third heart sound, fourth heart sound, jugular vein distension)
Table 3 Patients with LVEF < 40%

|                | Treatment Patterns (ACEI, ARB, or BB) | Treatment Patterns (Diuretic) |
|----------------|--------------------------------------|-------------------------------|
|                | Increase (n = 36,478) | No changes (n = 507,371) | Decrease (n = 34,091) | Rate Ratio for Treatment Increase | Rate Ratio for Treatment Decrease | No to Yes (n = 22,015) | No changes (n = 537,855) | Yes to No (n = 19,276) | Rate Ratio for Treatment Increase | Rate Ratio for Treatment Decrease |
| NYHA class change, % |
| Increase (n = 8452) | 8.1 | 83.8 | 7.8 | 1.5 | 1.3 | 6.1 | 89.8 | 4.0 | 1.9 | 1.1 |
| No changes (n = 156,801) | 5.5 | 88.3 | 6.0 | – | – | 3.3 | 93.2 | 3.5 | – | – |
| Decrease (n = 8370) | 7.7 | 85.1 | 7.1 | 1.4 | 1.2 | 4.5 | 91.9 | 3.7 | 1.4 | 1.1 |
| Dyspnea change, % |
| No to yes (n = 20833) | 145 | 80.4 | 4.8 | 2.5 | 0.9 | 92 | 88.0 | 2.8 | 2.6 | 0.9 |
| No changes (n = 435,120) | 58 | 88.6 | 5.4 | – | – | 36 | 93.3 | 3.2 | – | – |
| Yes to no (n = 13,026) | 43 | 83.8 | 11.6 | 0.7 | 2.2 | 27 | 92.2 | 5.1 | 0.8 | 1.6 |
| Orthopnea change, % |
| No to yes (n = 10720) | 134 | 82.0 | 4.5 | 2.2 | 0.8 | 87 | 88.5 | 2.8 | 2.4 | 0.8 |
| No changes (n = 463,734) | 60 | 88.1 | 5.7 | – | – | 37 | 93.0 | 3.3 | – | – |
| Yes to no (n = 7659) | 42 | 87.3 | 8.4 | 0.7 | 1.5 | 28 | 92.7 | 4.5 | 0.8 | 1.4 |
| Changes in signs, % |
| Increase (n = 246,34) | 140 | 79.4 | 6.3 | 2.4 | 1.1 | 96 | 87.0 | 3.5 | 2.7 | 1.0 |
| No changes (n = 275,342) | 59 | 88.2 | 5.7 | – | – | 35 | 93.1 | 3.4 | – | – |
| Decrease (n = 18,282) | 55 | 85.5 | 8.6 | 0.9 | 1.5 | 33 | 91.8 | 4.9 | 0.9 | 1.4 |

N = visit pairings; individual patients often represented more than once

ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta blocker, NYHA New York Heart Association, LVEF left-ventricular ejection fraction

*Treatment patterns were grouped into 1 of 3 categories: 'increase' (no to yes), 'decrease' (yes to no), or 'no change' in number of HF medication classes (ACEI, ARB, BB, and diuretic therapies)

Unit of analysis throughout the table is cardiology outpatient visits

Row percentages do not add up to 100% as a small number of treatment pattern changes that could not be determined were observed

Changes in number of physical signs of HF present out of 7 possible (rales, ascites, peripheral edema, hepatomegaly, third heart sound gallop, fourth heart sound gallop, jugular vein distension)
| Table 4 Patients ≤65 years of age |
|----------------------------------|
| **Treatment Patterns (ACEI, ARB, or BB)** | **Treatment Patterns (Diuretic)** |
| **Increase**  | **No to Yes**  | **No Changes**  | **Yes to No**  | **Decrease**  | **No Changes**  | **Yes to No**  | **Rate Ratio for Treatment Increase** | **Rate Ratio for Treatment Decrease** |
| \( n = 57,100 \) | \( n = 30326 \) | \( n = 802,586 \) | \( n = 32,273 \) | \( n = 57,100 \) | \( n = 754,371 \) | \( n = 802,586 \) | | |
| NYHA class change, %
| Increase | 8.2 | 83.4 | 80 | 1.3 | 1.4 | 5.9 | 898 | 4.2 | 2.0 | 1.1 |
| \( n = 6604 \) | | | | | | | | | |
| No changes | 6.2 | 87.6 | 59 | – | – | 3.0 | 933 | 3.7 | – | – |
| \( n = 247,910 \) | | | | | | | | | |
| Decrease | 8.3 | 84.2 | 72 | 1.3 | 1.2 | 4.5 | 907 | 4.8 | 1.5 | 1.3 |
| \( n = 7455 \) | | | | | | | | | |
| Dyspnea change, %
| No to yes | 14.0 | 80.3 | 53 | 2.3 | 1.0 | 7.8 | 891 | 3.1 | 2.4 | 0.9 |
| \( n = 25,590 \) | | | | | | | | | |
| No changes | 6.2 | 88.2 | 53 | – | – | 3.3 | 933 | 3.4 | – | – |
| \( n = 665,509 \) | | | | | | | | | |
| Yes to no | 5.0 | 77.0 | 17.7 | 0.8 | 3.3 | 3.0 | 875 | 9.6 | 0.9 | 2.8 |
| \( n = 17,044 \) | | | | | | | | | |
| Orthopnea change, %
| No to yes | 12.3 | 82.4 | 49 | 1.9 | 0.9 | 6.7 | 904 | 2.9 | 1.9 | 0.8 |
| \( n = 12,903 \) | | | | | | | | | |
| No changes | 6.5 | 87.5 | 57 | – | – | 3.5 | 929 | 3.7 | – | – |
| \( n = 729,881 \) | | | | | | | | | |
| Yes to no | 4.8 | 81.1 | 13.8 | 0.7 | 2.4 | 2.9 | 901 | 7.0 | 0.8 | 1.9 |
| \( n = 9829 \) | | | | | | | | | |
| Changes in signs, %
| Increase | 12.8 | 81.1 | 57 | 2.0 | 1.0 | 7.9 | 887 | 3.4 | 2.4 | 1.0 |
| \( n = 25,689 \) | | | | | | | | | |
| No changes | 6.4 | 87.9 | 55 | – | – | 3.3 | 932 | 3.5 | – | – |
| \( n = 428,162 \) | | | | | | | | | |
| Decrease | 6.3 | 81.0 | 12.2 | 1.0 | 2.2 | 3.2 | 891 | 7.7 | 1.0 | 2.2 |
| \( n = 21,623 \) | | | | | | | | | |

ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, BB: beta blocker, NYHA: New York Heart Association

*A treatment patterns were grouped into one of three categories: ‘increase’ (no to yes), ‘decrease’ (yes to no), or ‘no change’ in number of HF medication classes (ACEI, ARB, BB, and Diuretic therapies)

*bUnit of analysis throughout the table is cardiology outpatient visits

cRow percentages do not add up to 100% as a small number of treatment pattern changes that could not be determined were observed

*dChanges in number of physical signs of HF present out of 7 possible (rales, ascites, peripheral edema, hepatomegaly, third heart sound gallop, fourth heart sound gallop, jugular vein distension)
Table 5 Patients > 65 years of age

|                           | Treatment Patterns (ACEI, ARB, or BB) | Treatment Patterns (Diuretic) |
|---------------------------|--------------------------------------|-------------------------------|
|                           | Increase (n = 136,416) | No Changes (n = 1,856,676) | Decrease (n = 135,019) |
|                           | Rate Ratio for Treatment Increase   | Rate Ratio for Treatment Decrease |
| NYHA class change, %  
  Increase (n = 176,38) | 7.3 844 79 1.3 13 | 59 896 45 1.7 1.2 |
| No changes (n = 541,651) | 5.8 877 62 – – | 34 927 39 – – |
| Decrease (n = 169,67) | 7.6 849 72 1.3 12 | 44 91.1 45 1.3 1.2 |
| Dyspnea change, %  
  No to yes (n = 65,382) | 15.3 792 5.1 2.6 09 | 96 875 29 2.7 0.8 |
| No changes (n = 1,579,400) | 5.9 882 57 – – | 36 928 35 – – |
| Yes to no (n = 46,792) | 4.1 764 19.1 0.7 34 | 25 869 106 0.7 3.0 |
| Orthopnea change, %  
  No to yes (n = 33,628) | 15.2 800 45 2.5 08 | 90 885 26 2.4 0.7 |
| No changes (n = 1,706,439) | 6.2 876 60 – – | 38 925 38 – – |
| Yes to no (n = 29,351) | 3.5 794 16.8 0.6 28 | 24 889 88 0.6 2.3 |
| Changes in signs, %  
  Increase (n = 72,716) | 13.0 805 6.1 2.1 10 | 90 875 35 2.6 1.0 |
| No changes (n = 1,037,901) | 6.1 878 59 – – | 35 928 37 – – |
| Decrease (n = 62,803) | 5.1 81.1 13.5 0.8 23 | 31 885 83 0.9 2.2 |

N = visit pairings; individual patients often represented more than once
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta blocker, NYHA New York Heart Association

aTreatment patterns were grouped into 1 of 3 categories: 'increase' (no to yes), 'decrease' (yes to no), or 'no change' in number of HF medication classes (ACEI, ARB, BB, and diuretic therapies)

bUnit of analysis throughout the table is cardiology outpatient visits

cRow percentages do not add up to 100% as a small number of treatment pattern changes that could not be determined were observed

dChanges in number of physical signs of HF present out of 7 possible (rales, ascites, peripheral edema, hepatomegaly, third heart sound gallop, fourth heart sound gallop, jugular vein distention)
HF, and atrial fibrillation) from outpatient practices across the U.S. [19]. Here, the PINNACLE Registry has provided preliminary insights into what occurs at ambulatory cardiology visits for patients with HF.

Adherence to treatment guidelines has been shown to improve outcomes of patients with HF, including health-related quality of life. Poor health-related quality of life has been associated with many factors including greater symptom burden in patients with HF [7]. A patient-centered focus on symptom deterioration may facilitate more rapid and adequate care and reduce the need for hospitalizations [8, 25]. In the current study, a lack of change in the index HF treatment was most often observed in the presence of worsening symptoms and signs. Previous studies have reported various rationales for not modifying treatment patterns in accordance with HF treatment guidelines, including medical reasons (e.g., tolerability) and human reasons (e.g., clinical inertia, patient preferences) [26]. Studies have also found lack of adherence to HF guidelines may more often be seen in older patients or those with comorbidities, due to concerns with clinical complexity of treatment and limited potential benefits for these patients [27]. Because of the nature of PINNACLE data, we are unable to comment on the reasons here, other than to say that these patterns were seen across LVEF and age groups. Future research could examine the association of dosage regimen optimization with symptom control to inform clinical practice.

A number of limitations with regard to the current study should be considered. Because indications for BB, ACEI, ARB, aldosterone antagonists, and newer agents are all dependent on LVEF, the lack of LVEF data in nearly half of patients limits the analysis. Fortunately, with the large sample size in PINNACLE, we were able to look at the subgroup of patients with HF with reduced LVEF and found that medication changes in this group were similarly low. The loss of detailed medication information when data were transformed for analysis (i.e., type of diuretic and dosage information) significantly limited the ability to understand the scope of therapy adjustments occurring at clinic visits [18, 28, 29]. For example, a patient could have had furosemide dose increased and spironolactone added, but these medication changes would still be classified by PINNACLE as “unchanged” diuretic. PINNACLE data capture does not allow for an analysis of HF medication dosing. Continuous advances in the interface and processing of electronic health records within PINNACLE are ongoing and should improve medication data capture in the future. Finally, outpatient cardiology practices voluntarily participating in the PINNACLE Registry may not optimally represent practice patterns across the U.S.; however, the characteristics of practices and patients in PINNACLE have been shown to mirror the broader U.S. cardiology ambulatory population.

Conclusions
Serial ambulatory HF visits in U.S. cardiology practices were common and rarely involved changes in symptoms and signs. HF medications were seldom added or removed at a class level. These findings may suggest opportunities for more proactive medication class optimization or, alternatively, for more symptom-based visit scheduling.

Abbreviations
ACEI: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; BB: Beta blockers; CV: Cardiovascular; HF: Heart failure; LVEF: Reduced left-ventricular ejection fraction; NCDR: National cardiovascular data registry; NYHA: New York heart association; PINNACLE: Practice innovation and clinical excellence; S1 gallop: Third heart sound; S4 gallop: Fourth heart sound

Acknowledgments
Write All Inc. (Sonoma, CA) provided medical writing and editorial assistance for this manuscript.

Funding
Funding for this study was provided by Novartis Pharmaceuticals Corporation and a NIH grant K23HL105896. The PINNACLE Registry is an initiative of the American College of Cardiology.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available at the PINNACLE registry, https://cvquality.acc.org/NCDR-Home/data-collection/pinnacle-data-collection.

Authors’ contributions
LA, FT, PJ, TB, AP, and ST have met the criteria for authorship set forth by the International Committee for Medical Journal Editors (ICMJE), and have contributed equally to the following: 1) conception and study design, or analysis and interpretation of data; or both; 2) design or analysis and interpretation of data, or both; 3) drafting of the manuscript or revising it critically for important intellectual content; and 4) final approval of the manuscript submitted. This article has not been published or accepted for publication in any other venue and is not under consideration at any other journal. The concepts have been presented as a poster consideration at the American Heart Association (AHA) Annual Meeting in New Orleans, LA; November 14, 2016.

Ethics approval and consent to participate
This study did not require informed consent or institutional review board approval because all data were accessed using techniques compliant with the Health Insurance Portability and Accountability Act of 1996. Thus, no identifiable protected health information was extracted during the course of the study period.

Competing interests
LA. Allen has received research grants from the NIH/NHLBI, PCORI, and AHA as well as consultant/advisory board fees from Janssen and Novartis Pharmaceuticals Corporation. For this manuscript, LA’s time was partially supported by NIH grant K23HL105896. S.J. Turner is an employee of Novartis Pharmaceuticals Corporation. F. Tang, P. Jones, T. Breeding, and A. Ponirakis declare no conflict of interest.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Cardiology, University of Colorado School of Medicine, Anschutz Medical Campus, 12631 E. 17th Avenue, Academic Office 1, #7019, Mail Stop B130, Aurora, CO 80045, USA. 2Saint Luke’s Mid America Heart Institute, 4401 Wornall Road, Kansas City, MO 64111, USA. 3American College of Cardiology, Heart House, 2400 N Street NW, Washington, DC 20037, USA. 4Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, One Health Plaza 125/3410B, East Hanover, NJ 07936-1080, USA.
